Lytix Biopharma Dividend

Dividend criteria checks 0/6

Lytix Biopharma does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	1.5%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-NOK 1.54
Dividend yield forecast	n/a

Recent dividend updates

No updates

Recent updates

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if LYTIX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LYTIX's dividend payments have been increasing.

Dividend Yield vs Market

Lytix Biopharma Dividend Yield vs Market

How does LYTIX dividend yield compare to the market?
Segment	Dividend Yield
Company (LYTIX)	n/a
Market Bottom 25% (NO)	3.5%
Market Top 25% (NO)	7.7%
Industry Average (Biotechs)	1.5%
Analyst forecast (LYTIX) (up to 3 years)	n/a

Notable Dividend: Unable to evaluate LYTIX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LYTIX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate LYTIX's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as LYTIX has not reported any payouts.

Lytix Biopharma Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

We're Keeping An Eye On Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

New major risk - Financial position

New major risk - Share price stability

New minor risk - Shareholder dilution

Lytix Biopharma Announces Approval of the Phase II Study in Early-Stage Skin Cancer (Melanoma) Representing A Significant Commercial Opportunity

Lytix Biopharma AS has filed a Follow-on Equity Offering in the amount of NOK 55.071362 million.

Lytix Biopharma AS has filed a Follow-on Equity Offering in the amount of NOK 55.071362 million.

Full year 2023 earnings released

We're A Little Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

Lytix Biopharma AS to Report Q4, 2023 Results on Feb 15, 2024

Lytix Biopharma as Announces Encouraging Results from ATLAS-It-04 Study Published in Oncoimmunology

Third quarter 2023 earnings released

We're Keeping An Eye On Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

New major risk - Financial position

Lytix Biopharma AS Completes Recruitment of 20 Patients in the ATLAS-IT-05 Trial

Lytix Biopharma's Licensing Partner Verrica Pharmaceuticals Inc. Reports Interim Phase 2 Data with LTX-315

We Think Lytix Biopharma (OB:LYTIX) Can Afford To Drive Business Growth

Full year 2022 earnings released

Companies Like Lytix Biopharma (OB:LYTIX) Are In A Position To Invest In Growth

Lytix Biopharma AS to Report Fiscal Year 2022 Results on Mar 30, 2023

Third quarter 2022 earnings released

High number of new and inexperienced directors

Lytix Biopharma Announces Site Activation for the ATLAS-IT-05 Study in Three European Countries

Lytix Biopharma AS Presents Compelling Data in Collaboration with Research Groups At National Cancer Institute and Weill Cornell Medicine, USA

Lytix Biopharma AS Announces Approval to Expand the ATLAS-IT-05 Study to Europe

Lytix Biopharma AS Appoints Stephen Worsley as Chief Business Officer

Co-Founder & CEO recently bought kr100k worth of stock

Lytix Biopharma AS Announces Data from Its Atlas-It-04 Trial in Patients with Progressive Metastatic Soft Tissue Sarcoma

We're Not Very Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

Lytix Biopharma as Announces That LTX-315 with Adoptive Cell Therapy Has Been Shown to Generate Tumor-Specific T Cells and Stabilize the Disease in Patients with Metastatic Soft Tissue Sarcoma (STS)

Less than half of directors are independent

Full year 2021 earnings: Revenues in line with analyst expectations

Lytix Biopharma announces Grant of 3 Million NOK from Oslo Regional Research Fund

We're Not Very Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

Third quarter 2021 earnings: Revenues in line with analyst expectations

We Think Lytix Biopharma (OB:LYTIX) Can Afford To Drive Business Growth

Lytix Biopharma Initiates Phase II Combination Study in the US with LTX-315 and Pembrolizumab in Patients with Solid Tumors

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies